Akero Therapeutics, Inc. (AKRO)
| Market Cap | 1.30B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -119.63M |
| Shares Out | 55.71M |
| EPS (ttm) | -2.28 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,294,413 |
| Open | 24.17 |
| Previous Close | 24.02 |
| Day's Range | 23.10 - 24.17 |
| 52-Week Range | 11.25 - 58.38 |
| Beta | -0.51 |
| Analysts | Strong Buy |
| Price Target | 44.43 (+90.28%) |
| Earnings Date | Nov 13, 2023 |
About AKRO
Akero Therapeutics, Inc., a clinical-stage company, engages in the development of transformational treatments for patients with serious metabolic diseases, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company is also conducting a Phase 2b clinical trial to evaluate EFX in the treatmen... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for AKRO stock is "Strong Buy." The 12-month stock price forecast is $44.43, which is an increase of 90.28% from the latest price.
News
Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program
Week 96 Phase 2b HARMONY Results for Treatment of Patients with Pre-Cirrhotic NASH/MASH (F2-F3) to be Reported in March 2024
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Akero Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / November 22, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Akero Therape...
Akero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
-- Phase 3 SYNCHRONY studies actively screening and on track to begin enrolling by the end of 2023 -- SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: A...
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Akero Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / November 13, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Akero Therape...
Akero Therapeutics to Present Late-Breaking Oral and Poster Presentations on EFX at AASLD's The Liver Meeting® 2023
Phase 2b SYMMETRY 36-week data, including new subgroup analysis, showed that EFX is active in patients with advanced cirrhosis and support continued development of EFX for treatment of cirrhosis due t...
Akero Therapeutics to Present at Upcoming Healthcare Conferences in November
SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabo...
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Akero Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 19, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Akero Therapeu...
Akero Therapeutics to Present at the H.C. Wainwright 7th Annual NASH Virtual Investor Conference
SOUTH SAN FRANCISCO, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabo...
Stocks trending October 10, 2023: Akero Therapeutics, Palantir, Hyatt Hotels
Stocks are higher in early trading on dovish commentary from Federal Reserve officials. Hyatt Hotels Corporation (H) shares jump as the company will be replacing National Instruments (NATI) on the S&P...
Akero Therapeutics stock crashed 65% on Tuesday: what happened?
Akero Therapeutics Inc (NASDAQ: AKRO) crashed more than 65% this morning after reporting interim results of SYMMETRY – a Phase 2b study of its non-alcoholic steatohepatitis (NASH) candidate. Akero The...
Akero Therapeutics shares plunge on liver disease treatment's mixed results
Akero Therapeutics Inc. shares AKRO, -3.56% fell more than 60% premarket on Tuesday after the company released an update on its lead product candidate, a treatment for nonalcoholic steatohepatitis, a ...
Akero's drug for fatty liver disease misses main trial goal
Akero Therapeutics said on Tuesday a mid-stage trial for its drug to treat a type of fatty liver disease showed improvement in patients, but the results were not statistically significant, sending its...
Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lip
22% (28mg EFX) and 24% (50mg EFX) of patients experienced at least a one-stage improvement in liver fibrosis with no worsening of NASH by week 36, compared to 14% for placebo
Akero Therapeutics to Present Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH
Investor webcast on Tuesday, October 10 at 8:00 a.m. ET to present clinical data Investor webcast on Tuesday, October 10 at 8:00 a.m. ET to present clinical data
Akero Therapeutics Announces Publication of the Harmony Phase 2b Trial Results in The Lancet Gastroenterology & Hepatology
As previously reported, the study met its primary endpoint of improvement in liver fibrosis without worsening of NASH at week 24, and key secondary endpoints including NASH resolution without worsenin...
Akero Therapeutics to Present at Upcoming Healthcare Conferences in September
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabo...
Akero Therapeutics to Report Results of Phase 2b SYMMETRY Study in October 2023
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabo...
Akero Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
-- Positive Results from Phase 2b SYMMETRY Cohort D, an expansion cohort of Type 2 diabetic, pre-cirrhotic NASH patients treated with EFX or placebo in combination with a GLP-1 receptor agonist, repor...
Weight-loss drugs in development aim to replace injections with pills
Wall Street's obsession with next-generation obesity and diabetes treatments intensified over the weekend as drugmakers presented new clinical-trial data on the drugs — including weight-loss pills in ...
Akero Therapeutics Presents Analyses of Phase 2b HARMONY Study at the 2023 International Liver Congress Reinforcing and Characterizing EFX-Related Improvements in Liver Histopathology
Data show changes in non-invasive tests in EFX-treated patients were associated with improvements in NASH histopathology and highlight dose-dependent responses Data show changes in non-invasive tests ...
3 Mid Caps You Haven't Heard Of But Need To Know About
There have been plenty of headlines in recent weeks regarding the influence a few tech titans are having on the broader market rally that's underway, with some voices suggesting the S&P 500 would actu...
Akero says NASH drug shown to reduce liver fat by 65% in some patients
Akero Therapeutics Inc said on Monday data from a mid-stage study showed its experimental therapy reduced liver fat by 65% in certain patients with a type of fatty liver disease called nonalcoholic st...
Akero Therapeutics' Phase 2b SYMMETRY Cohort D Study Met Safety & Tolerability Endpoints and Showed Adding EFX to GLP-1 Therapy Significantly Improved Non-Invasive Markers of NASH-Related Disease
Patients treated with EFX for 12 weeks combined with GLP-1 achieved a 65% relative reduction in liver fat, compared to a 10% relative reduction for GLP-1 alone
Akero Therapeutics to Present Results from Phase 2b Expansion Cohort of SYMMETRY Trial Evaluating Efruxifermin in Combination with GLP-1
Investor webcast on Monday, June 5 at 8:00 a.m. ET to present clinical data Investor webcast on Monday, June 5 at 8:00 a.m. ET to present clinical data
Akero Therapeutics to Present at the Jefferies Healthcare Conference
SAN FRANCISCO, May 31, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease mar...